Daphne Zohar
@daphnezohar
Founder & CEO of @SeaportTX. Co-founder Karuna Tx (now at BMS). previously Founder & CEO @PureTechH. Cofounder/host @BiotechCH. Board Exec committee @IamBiotech
Spending the day in DC w/ Biotechnology Innovation Organization leadership & board with a focus on policies to “Make American Biotechnology Accelerate” to help support the industry in advancing new medicines to patients and also hopefully help with the overhang to capital markets…
Another private biotech gets acquired - up to $1.6B ($1.15B upfront) Congrats to @GMariggi, Emmanuel Hanon and the Vicebio and @medicxi teams @sciencescanner $XBI $IBB @sanofi
Thrilled to announce that @medicxi portfolio company Vicebio has entered into an exclusive agreement to be acquired by @sanofi for $1.6B, including an upfront payment of $1.15B 🚀🚀 prnewswire.com/news-releases/…
I took a tour of @daphnezohar's new offices today in the Seaport.🐟
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐓𝐨𝐮𝐫: BiotechTV visited the new offices of @SeaportTx today and was given a tour by Founder & CEO @daphnezohar.
Patent cliff pushing pharma companies earlier in deal making $XBI $IBB good summary by the FT
1/Here’s an excellent Financial Times article which accurately describes the problematic situation which many big Pharma companies such as $PFE $JNJ $BMY $ABBV $LLY $MRK $SNY and others are now facing - the upcoming patent cliff scenario. With IP rights which are about to expire…
Positive for sector vs other options. FDA to Name Biotech Executive George Tidmarsh as RFK Jr.'s Top Drug Regulator. HT @adamfeuerstein $XBI $IBB bloomberg.com/news/articles/…
Look again at that dot. That's here. That's home. That's us. On it everyone you love, everyone you know, everyone you ever heard of, every human being who ever was, lived out their lives. The aggregate of our joy and suffering, thousands of confident religions, ideologies, and…
Heartbreaking, this entire Syrian Christian family of twenty was murdered by jihadists in Sweida. Druze and Christians in Syria are being slaughtered, raped, tortured, beheaded. Where are the eyes of the world?
𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐂𝐄𝐎 𝐒𝐢𝐬𝐭𝐞𝐫𝐡𝐨𝐨𝐝: As CEO, Sophie Kornowski sold Boston Pharmaceuticals to GSK earlier this year for up to $2 billion. She shares her thoughts on the biopharma business and leadership with @daphnezohar. Full video: biotechtv.com/post/biotech-c…
Pleased to announce the first patient has been dosed in our Ph2b BUOY-1 study of GlyphAllo™ (SPT-300) in #MDD w/ or w/o anxious distress, an important milestone for Seaport’s pipeline that brings us closer to a potential new treatment for patients w/ MDD: bit.ly/3Uhn3YB
Remember those families raising money to afford an expensive gene therapy to save their kid? The kind of thing that makes pharma hated. On the other end of the spectrum is what happens when there’s no pharma interest. Parents raising money for a small clinical study. Maybe…
Some good suggestions here for reducing onerous & expensive SEC reporting requirements for small/midsize biotechs from my colleague & fellow @IAmBiotech board member Frank Watanabe (CEO of Arcutis) bio.news/federal-policy… $ARQT $XBI $IBB
In biotech, “not nearly as despondent” sounds bullish
Cowen: "Sentiment toward biotech stocks improved through the month of June and enters H2 above the nadir reached earlier in the Spring. Investors remain unenthusiastic, but are not nearly as despondent as they had been"
A great post for raising money from VCs.... "Best Practices for Pitching, Geared Towards First-Time Founders" - from @AtlasVenture's @AimeeRaleigh13 ... lifescivc.com/2025/07/best-p…
San Quentin prison holds their first ever father-daughter prom, for some inmates it was the first time they’ve ever spent face to face time with their daughters. Very cool. One father, Steven Embrey, got to hug his 28-year-old daughter one last time before she was tragically…
Today, I introduced the Bipartisan Pharmacy Benefit Manager (PBM) Reform Act. For decades, PBMs have been STEALING patients’ hope and health. As a pharmacist, I’ve seen firsthand the heartbreaking impact of PBMs— forcing families to choose between groceries and medicine. It’s…
If Makary is serious about drug-review transparency, publish CRLs when they're issued. That will be the true test. Disclosing old CRLs on drugs that were later approved doesn't tell you very much. Will it incentivize companies today to be more transparent and honest about…